Previous 10 | Next 10 |
VirTra (VTSI) +56% on Q4 results.Color Star Technology Co., Ltd. (CSCW) +56% as company to develop NFT.Performant Financial Corporation (PFMT) +26%.Monopar Therapeutics (MNPR) +18% on preclinical update of its uPA.Moleculin Biotech (MBRX) +18% on FDA's fast track desi...
Immatics (IMTX): FY Net loss of $281.7MRevenue of $38.4M (+69.9% Y/Y) beats by $3.31M.Shares +7.35% PM.Press Release For further details see: Immatics beats on revenue
Phase 1a data update from clinical ACTengine ® programs demonstrated first anti-tumor activity at early phases of dose escalation in heavily pre-treated solid cancer patients Enrollment across clinical ACTengine ® IMA200 trial series continues t...
Shares of Immatics (NASDAQ: IMTX) were trading higher on Wednesday after the biopharmaceutical company announced positive data from a phase 1 clinical trial for several of its pipeline candidates. As of 3:25 p.m. EDT, Immatics' stock was up by 25.9%, after soaring by as much as 58.4...
Gainers: Takung Art (TKAT) +122%.Zhongchao (ZCMD) +52%.Oriental Culture (OCG) +43%.Integrated Media Technology (IMTE) +43%.Immatics (IMTX) +33%.Puyi (PUYI) +29%.Willis Lease Finance (WLFC) +24%.Lipocine (LPCN) +24%.Liquid Media (YVR) +21%.Sigma Labs (SGLB) +20%.Losers: Sun...
Gainers: Zhongchao (ZCMD) +53%, Immatics (IMTX) +42%, Lipocine (LPCN) +23%, FSD Pharma (HUGE) +18%, Nabriva Therapeutics (NBRV) +18%.Losers: SunLink Health Systems (SSY) -28%, Rubius Therapeutics (RUBY) -17%, CHF Solutions CHFS&...
Immatics N.V. (IMTX) announces updated data from the dose escalation cohorts of the company’s ongoing Phase 1 trials for its engineered Adoptive Cell Therapy approach (also known as TCR-T).Shares up more than 30% premarket.The treatment of patients with ACTengine ca...
Company to host conference call on Wednesday, March 17 at 8:30 am EST · First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation · Tumor shrinkage observed in 8 out of 1...
Immatics is a very early-stage biotech company with most assets still in the pre-clinical phase. They have a proprietary oncology platform that generates T cell targets against Cancer-Testis Antigens. Despite being exceptionally early in development, Immatics already has establish...
Immatics (IMTX): Q3 GAAP EPS of -€2.82.Revenue of €7.87M (+55.8% Y/Y)Press Release For further details see: Immatics reports Q3 results
News, Short Squeeze, Breakout and More Instantly...
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-conc...
2024-07-12 10:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...